About Tesamorelin
What is Tesamorelin?
Tesamorelin is a stabilized synthetic GHRH(1–44) analogue first characterized as TH9507. The N-terminal modification dramatically extends plasma half-life relative to native GHRH, enabling reproducible somatotropic-axis stimulation in research protocols.
Tesamorelin has been most heavily studied for its effects on the GH/IGF-1 axis and on visceral adipose tissue in HIV-associated lipodystrophy research.
How it's studied — mechanism
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotrophs, driving pulsatile release of endogenous growth hormone. Downstream:
- GH-mediated hepatic IGF-1 synthesis
- Lipolytic signaling at visceral adipocytes
- Net effects on body-composition markers in published trials
Amino acid sequence
Primary structure
GHRH(1–44) analogue · N-acyl (trans-3-hexenoic acid) at Tyr¹Published research
The following primary sources are provided to support qualified-researcher review. Inclusion is for reference only and does not constitute medical advice or therapeutic claim.
Primary literature
Research use only
Tesamorelin is sold strictly for in-vitro research by qualified researchers and is not approved by the FDA for any therapeutic indication. It is not intended to diagnose, treat, cure, or prevent any disease, and is not intended for human or veterinary consumption. All statements on this page describe published research literature and do not constitute medical claims. By purchasing you agree to use Tesamorelin only in accordance with applicable federal, state, and local law.